Methods for Inhibiting the Development of Huntington's Disease
First Claim
Patent Images
1. A method of treating a female individual having Huntington'"'"'s Disease (HD) or a HD gene having greater than or equal to about 36 CAG repeats;
- the method comprises;
a. selecting a female individual having HD or a HD gene having greater than or equal to about 36 CAG repeats; and
b. administering to the female individual an amount of estrogen, a precursor thereof, or a combination thereof, wherein the amount of administration to the female individual ranges from about 0.025 mg to about 10 mg;
wherein the female individual with HD or HD gene having greater than or equal to about 36 CAG repeats is treated.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to Huntington'"'"'s disease and more specifically to methods for inhibiting the development of or treating Huntington'"'"'s disease by administering estrogen, testosterone, precursors thereof or combinations thereof.
5 Citations
44 Claims
-
1. A method of treating a female individual having Huntington'"'"'s Disease (HD) or a HD gene having greater than or equal to about 36 CAG repeats;
- the method comprises;
a. selecting a female individual having HD or a HD gene having greater than or equal to about 36 CAG repeats; and b. administering to the female individual an amount of estrogen, a precursor thereof, or a combination thereof, wherein the amount of administration to the female individual ranges from about 0.025 mg to about 10 mg;
wherein the female individual with HD or HD gene having greater than or equal to about 36 CAG repeats is treated. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 16)
- the method comprises;
-
9. A method of treating a male individual having HD or a HD gene having greater than or equal to about 36 CAG repeats;
- the method comprises;
a. selecting a male individual having HD or a HD gene having greater than or equal to about 36 CAG repeats; and b. administering to a male individual an amount of testosterone, a precursor thereof, or a combination thereof, wherein the amount of administration of a male individual ranges from about 1 mg to about 35 g; wherein the male individual with HD or HD gene having greater than or equal to about 36 CAG repeats is treated. - View Dependent Claims (10, 11, 12, 13, 14, 15)
- the method comprises;
-
17. A method of reducing one or more symptoms associated with HD in a female individual, wherein the method comprises:
-
a. selecting the female individual having HD; and b. administering to the female individual an amount of estrogen, a precursor thereof, or a combination thereof, wherein the amount of administration to a female individual ranges from about 0.025 mg to about 10 mg;
wherein one or more symptoms associated with HD in the female individual is reduced, as compared to an individual with HD not subjected to step b. - View Dependent Claims (18, 19)
-
-
20. A method of reducing one or more symptoms associated with HD in a male individual, wherein the method comprises:
-
a. selecting the male individual having HD; and b. administering to the male individual an amount of testosterone, a precursor thereof, or a combination thereof, wherein the amount of administration of a male individual ranges from about 1 mg to about 35 g; wherein one or more symptoms associated with HD in the male individual is reduced, as compared to an individual with HD not subjected to step b. - View Dependent Claims (21, 22)
-
-
23. A method of preventing weight loss, or reducing the amount of weight loss in a female individual having HD, wherein the method comprises:
-
a. selecting the female individual having HD; and b. administering to the female individual an amount of estrogen, a precursor thereof, or a combination thereof, wherein the amount of administration to a female individual ranges from about 0.025 mg to about 10 mg; wherein weight loss is prevented or the amount of weight loss is reduced in the female individual with HD, as compared to an individual with HD not subjected to step b. - View Dependent Claims (24, 25)
-
-
26. A method of preventing weight loss, or reducing the amount of weight loss in a male individual having HD, wherein the method comprises:
-
a. selecting the male individual having HD; and b. administering to the male individual an amount of testosterone, a precursor thereof, or a combination thereof, wherein the amount of administration ranges from about 1 mg to about 35 g; wherein weight loss is prevented or the amount of weight loss is reduced in the male individual with HD, as compared to an individual with HD not subjected to step b. - View Dependent Claims (27, 28)
-
-
29. A method of treating a female individual having HD, the method comprises:
-
a. assessing the female individual for the presence or absence of HD or the presence of absence of a HD gene having between about 36 CAG repeats and about 120 CAG repeats; b. assessing one or more levels of estrogen, precursors thereof, or a combination thereof in the female individual to determine if the one or more levels is below a normal level; and c. administering to the female individual an amount of estrogen, a precursor thereof, or a combination thereof to maintain an average amount of estrogen at a level in the female individual between about 100 pg/ml to about 185 pg/ml. - View Dependent Claims (30)
-
-
31. A method of treating an male individual having HD, the method comprises:
-
a. assessing the male individual for the presence or absence of HD or the presence of absence of a HD gene having between about 36 CAG repeats and about 120 CAG repeats; b. assessing one or more levels of testosterone, precursors thereof, or a combination thereof in the male individual to determine if the one or more levels is below a normal level; and c. administering to the male individual an amount of testosterone, a precursor thereof, or a combination thereof to maintain an average of free testosterone at a level in the male individual between about 20 pg/ml to about 40 pg/ml, total testosterone is between 300 ng/dL and about 900 ng/dL, or both. - View Dependent Claims (32)
-
-
33. A method of treating a female individual having a trinucleotide repeat disorder, the method comprises:
-
a. selecting the female individual having a trinucleotide repeat disorder; and b. administering to the female individual an amount of estrogen, precursors thereof or a combination thereof; wherein the female individual having a trinucleotide repeat disorder is treated. - View Dependent Claims (34)
-
-
35. A method of treating a male individual having a trinucleotide repeat disorder, the method comprises:
-
a. selecting the male individual having a trinucleotide repeat disorder; and b. administering to the male individual an amount of testosterone, precursors thereof or a combination thereof; wherein the male individual having a trinucleotide repeat disorder is treated. - View Dependent Claims (36)
-
-
37. A method of inhibiting a mutant huntingtin protein in a female individual having HD, wherein the method comprises:
-
administering to the female individual an amount of estrogen, a precursor thereof or a combination thereof; wherein the mutant huntingtin protein is inhibited. - View Dependent Claims (38, 39)
-
-
40. A method of inhibiting a mutant huntingtin protein in a male individual having HD, wherein the method comprises:
-
administering to the male individual an amount of testosterone, a precursor thereof or a combination thereof; wherein the mutant huntingtin protein is inhibited. - View Dependent Claims (41, 42)
-
-
43. A method of treating a female individual having HD, the method comprises:
-
a. assessing a female individual for the presence or absence of HD or the presence of absence of a HD gene having between about 36 CAG repeats and about 120 CAG repeats to thereby obtain a female individual with HD; b. assessing a level of estrogen in the female individual to determine if the level of estrogen is below about 100 pg/ml; and c. administering to the female individual having HD and a level of estrogen below about 100 pg/ml, an amount of estrogen, a precursor thereof or a combination thereof, wherein the amount of administration to a female individual ranges from about 0.025 mg to about 10 mg; wherein the female individual with HD is treated.
-
-
44. A method of treating a male individual having HD, the method comprises:
-
a. assessing a male individual for the presence or absence of HD or the presence of absence of a HD gene having between about 36 CAG repeats and about 120 CAG repeats to thereby obtain a male individual with HD; b. assessing one or more levels of testosterone in the male individual to determine if the level of free testosterone is below about 20 pg/ml, or the level of total testosterone is below about 300 ng/dL; and c. administering to the male individual having HD and a level of free testosterone is below about 20 pg/ml, or the level of total testosterone is below about 300 ng/dL, an amount of testosterone, a precursor thereof or a combination thereof, wherein the amount of administration to a male individual ranges from about 1 mg to about 35 g; wherein the male individual with HD is treated.
-
Specification